Compare Nano Dimension Ltd - ADR (NNDM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs TG Therapeutics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.62 (market cap $342.07M), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: TG Therapeutics Inc is far larger — about 22.2× Nano Dimension Ltd - ADR's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | TGTX | |
|---|---|---|
Market Cap | $342.07M | $7.58B |
Sector | Technology | Health |
52-Week High | $2.14 | $59.06 |
52-Week Low | $1.21 | $26.94 |
Enterprise Value | -$62.77M | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.65, down 0.6% with a bullish technical signal from moving averages. The company shows revenue growth from $58M in 2024 to $102M in 2025 but faces significant profitability challenges with a net income margin of -135.18% and negative cash flow from operations. Recent strategic actions include cost-saving initiatives and the planned sale of MarkForged to Stratasys, aiming to reduce cash burn by $25M annually.
The outlook remains speculative due to persistent losses and cash burn, though asset sales and restructuring may stabilize finances. Investment opportunity hinges on successful execution of turnaround plans, while risks include ongoing operational losses, shareholder activism from Murchinson, and execution risks in strategic transitions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
